BACKGROUND: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. PATIENTS AND METHODS: Between June 2003-September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. RESULTS: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET- during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. CONCLUSIONS: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.
BACKGROUND: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. PATIENTS AND METHODS: Between June 2003-September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. RESULTS: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET- during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. CONCLUSIONS: The PET use for early (after two cycles) response assessment in HDpatients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.
Authors: Peter D Cole; Kathleen M McCarten; Richard A Drachtman; Pedro de Alarcon; Lu Chen; Tanya M Trippett; Cindy L Schwartz Journal: Pediatr Hematol Oncol Date: 2010-11 Impact factor: 1.969
Authors: Carsten Kobe; Markus Dietlein; Jeremy Franklin; Jana Markova; Andreas Lohri; Holger Amthauer; Susanne Klutmann; Wolfram H Knapp; Josee M Zijlstra; Andreas Bockisch; Matthias Weckesser; Reinhard Lorenz; Mathias Schreckenberger; Roland Bares; Hans T Eich; Rolf-Peter Mueller; Michael Fuchs; Peter Borchmann; Harald Schicha; Volker Diehl; Andreas Engert Journal: Blood Date: 2008-08-29 Impact factor: 22.113
Authors: Agostino Chiaravalloti; Roberta Danieli; Paolo Abbatiello; Barbara Di Pietro; Laura Travascio; Maria Cantonetti; Manlio Guazzaroni; Antonio Orlacchio; Giovanni Simonetti; Orazio Schillaci Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-22 Impact factor: 9.236
Authors: Lale Kostakoglu; Heiko Schöder; Jeffrey L Johnson; Nathan C Hall; Lawrence H Schwartz; David J Straus; Ann S LaCasce; Sin-Ho Jung; Nancy L Bartlett; George P Canellos; Bruce D Cheson Journal: Leuk Lymphoma Date: 2012-08-28